5.91

3.32% 0.19

After Hours: 5.97 0.06 +1.02%

Verrica Pharmaceuticals Inc (VRCA)

Overview News Price History Option Chain Financials Discussions Forecast

Verrica Pharmaceuticals Inc stock is traded at $5.91, with a volume of 59,976. It is up +3.32% in the last 24 hours and down -3.27% over the past month. Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Previous Close:

$5.72

Open:

$5.75

24h Volume:

59,976

Relative Volume:

0.45

Market Cap:

$101.53M

Revenue:

$35.58M

Net Income/Loss:

$-17.89M

P/E Ratio:

-8.6619

EPS:

-0.6823

Net Cash Flow:

$-17.74M

1W Performance:

+1.55%

1M Performance:

-3.27%

6M Performance:

+44.15%

1Y Performance:

+19.78%

1-Day Range:

$5.645

$5.965

1-Week Range:

$5.10

$6.00

52-Week Range:

$3.28

$9.8212

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name

Verrica Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

484-453-3300

Address

10 NORTH HIGH STREET, WEST CHESTER, PA

Employee

Twitter

Next Earnings Date

2026-03-11

Latest SEC Filings

VRCA's Discussions on Twitter

Compare VRCA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRCA Verrica Pharmaceuticals Inc	5.91	98.26M	35.58M	-17.89M	-17.74M	-0.6823
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy
Mar-22-23	Initiated	Jefferies	Buy
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-21	Initiated	RBC Capital Mkts	Outperform
Dec-24-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy
Jun-24-20	Initiated	Northland Capital	Outperform
Mar-24-20	Initiated	Needham	Buy
Feb-21-19	Initiated	H.C. Wainwright	Buy

View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

Apr 15, 2026

Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting - MyChesCo

Apr 15, 2026

Apr 13, 2026

Block Trades: Is Verrica Pharmaceuticals Inc benefiting from innovation trendsM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Apr 13, 2026

Aug Rallies: Is Verrica Pharmaceuticals Inc stock good for income investors2026 Decliners & Low Risk Growth Stock Ideas - baoquankhu1.vn

Apr 13, 2026

Aug Big Picture: Will Verrica Pharmaceuticals Inc announce a stock split2026 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Apr 10, 2026

Apr 09, 2026

EPS Watch: Is Verrica Pharmaceuticals Inc stock a value trapWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn

Apr 09, 2026

Verrica Pharmaceuticals announces acceptance of late-breaking abstract highlighting potential abscopal effect of VP-315 for the treatment of basal cell carcinoma at the upcoming 2026 Society for Investigative Dermatology annual meeting - marketscreener.com

Apr 09, 2026

Skin cancer drug data from Verrica wins late-breaker slot in Chicago - Stock Titan

Apr 09, 2026

Chart Watch: Will Verrica Pharmaceuticals Inc announce a stock splitMarket Volume Report & Real-Time Sentiment Analysis - baoquankhu1.vn

Apr 09, 2026

Apr 07, 2026

Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart.com

Apr 07, 2026

Apr 06, 2026

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com

Apr 06, 2026

Needham conference adds Verrica CEO; webcast runs live April 15 - Stock Titan

Apr 06, 2026

Mar 31, 2026

Published on: 2026-04-01 04:27:23 - baoquankhu1.vn

Mar 31, 2026

Market Trends: How does Verrica Pharmaceuticals Inc score in quality rankingsProfit Target & Safe Swing Trade Setups - baoquankhu1.vn

Mar 31, 2026

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Growth in Short Interest - MarketBeat

Mar 31, 2026

Published on: 2026-03-31 18:08:06 - baoquankhu1.vn

Mar 31, 2026

Mar 27, 2026

Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart.com

Mar 27, 2026

Mar 25, 2026

Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 25, 2026

Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN

Mar 25, 2026

Mar 23, 2026

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Mar 23, 2026

Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN

Mar 23, 2026

Mar 20, 2026

Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn

Mar 20, 2026

Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN

Mar 20, 2026

VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - weeklyvoice.com

Mar 20, 2026

VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - weeklyvoice.com

Mar 20, 2026

Mar 19, 2026

Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe

Mar 19, 2026

FinancialContentVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - FinancialContent

Mar 19, 2026

Mar 17, 2026

Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm

Mar 13, 2026

Mar 12, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail

Mar 12, 2026

Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart

Mar 12, 2026

Mar 11, 2026

Verrica Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat

Mar 11, 2026

Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN

Mar 11, 2026